Using siRNA-Based Anti-Inflammatory Lipid Nanoparticles for Gene Regulation in Psoriasis
In this study, we successfully developed a novel anti-inflammatory LNP, which demonstrated notable advantages in delivery capacity, anti-inflammatory effect, and targeting therapy against STAT3, providing new ideas and strategies for nucleic acid therapy of psoriasis. This LNP platform could be broadly applicable to various inflammatory conditions, offering a versatile tool for targeted gene modulation and inflammation control.
Authors
- Yufei Cao (ORCID: https://orcid.org/0000-0002-4742-4009)
- Aizhong Zeng (ORCID: https://orcid.org/0000-0002-3328-3153)
- Wei Guo (ORCID: https://orcid.org/0000-0001-6212-8390)
- Ping Wang (ORCID: https://orcid.org/0000-0001-6474-2722)
- Yuanyuan Liu (ORCID: https://orcid.org/0000-0001-8107-9731)
Institutions
- China Pharmaceutical University (CN)
Publication Details
- Journal
- International Journal of Nanomedicine
- Published
- 2025-04-01
- DOI
- https://doi.org/10.2147/ijn.s504639
- Citations
- 7
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 9.52